جست‌وجوی استاد و پژوهشگر

Nichole Maughanمشاهده پروفایل

استادیار

• Radiopharmaceutical Therapy
• Radioembolization
• Medical Physics
• +۵ مورد دیگر

Nichole Maughan serves as Assistant Professor of Radiation Oncology in the Division of Medical Physics at Washington University School of Medicine in St. Louis. She joined the physics faculty in 2020 after completing her Medical Physics residency at the same institution. BS in Physics from Brigham Young University (2011) MS in Physics from Brigham Young University (2013) MS in Biomedical Engineering from Washington University in St. Louis (2016) PhD in Biomedical Engineering from Washington University in St. Louis (2017) Postdoctoral Research in Radiation Oncology at Washington University School of Medicine (2017) Medical Physics Residency at Washington University School of Medicine (2019) Dr. Maughan's research focuses on imaging and dosimetry of radiopharmaceutical therapy, with particular expertise in Yttrium-90 microsphere radioembolization for liver cancer and newer Lutetium-177 therapies for prostate cancer. Her doctoral research centered on post-procedural PET/MR imaging and dosimetry of yttrium-90 microspheres following hepatic radioembolization, and during residency her interests expanded to include broader radiopharmaceutical therapies. Her publication record demonstrates consistent contributions to the field of radiopharmaceutical therapy, with recent work addressing safety protocols, program implementation, dosimetry validation, and clinical outcomes. Her research spans technical aspects of imaging and dosimetry, clinical implementation of new therapies, safety protocols, and patient outcomes across various cancer types. As a clinical physicist, Dr. Maughan bridges the gap between medical physics principles and practical radiation oncology applications, contributing significantly to the advancement of targeted radiation therapies.

Fredrik Hedeerمشاهده پروفایل

مدرس مشاور

• Cardiac Imaging
• Myocardial Perfusion
• Nuclear Cardiology
• +۳ مورد دیگر

Fredrik Hedeer is a Consultant and Researcher affiliated with Lund University and the Lund Cardiac MR Group . His clinical and research focus lies in cardiovascular imaging , particularly comparing diagnostic modalities like myocardial perfusion SPECT (MPS) and cardiac magnetic resonance imaging (CMR) for assessing myocardial injury and perfusion in patients with suspected ischemic heart disease. Specializes in digital SPECT techniques and CMR correlation Active in UN SDG-related research (Radiology, Cardiology) Collaborates internationally on myocardial perfusion studies His work emphasizes diagnostic accuracy improvement and understanding perfusion dynamics under stress/rest conditions. Current research explores sex-based differences and comorbidity impacts in chronic coronary syndrome patients. Key collaborations include teams working on hybrid imaging modalities and radiotracer development . Publications demonstrate expertise in cardiovascular magnetic resonance, positron emission tomography, and multimodal imaging validation.

Vaseem U. Chengaziمشاهده پروفایل

استاد بالینی

• Nuclear Medicine
• Medical Imaging
• Radiology
• +۳ مورد دیگر

Vaseem U. Chengazi, M.D., Ph.D., is a Clinical Professor in the Department of Imaging Sciences at the University of Rochester School of Medicine and Dentistry. He specializes in nuclear medicine, integrating expertise in physics, mathematics, and computer science to advance diagnostic imaging and patient care. As part of the University of Rochester Medical Faculty Group (URMFG) and Accountable Health Partners (AHP), he contributes to a multidisciplinary network spanning over 19 departments and 2,000 providers. MBBS, King Edward Medical College, Lahore (Pakistan), 1987 Fellowship, Nuclear Medicine, St. Bartholomew's Hospital (England), 1993-1996 Fellowship, Center for Nuclear Studies, 1989-1990 Fellowship, University of Rochester Medical Center, 1997-1998 Chengazi’s research focuses on nuclear medicine applications in oncology, endocrinology, and neurology. His work spans PET/CT coregistration , SPECT imaging , and radioimmunoscintigraphy , with an emphasis on improving diagnostic accuracy and therapeutic outcomes. Key areas include thyroid cancer , prostate cancer , and sleep disorders . His publications highlight trends in hybrid imaging modalities (PET-CT, SPECT), radiopharmaceuticals , and clinical translation of nuclear medicine . Articles address topics like thyroid stunning , prostate cancer imaging , and neurological disorder diagnostics , reflecting interdisciplinary innovation. The Shu-Ren Lin Award (2005-2006) for senior faculty teaching The Shu-Ren Lin Award (1998-1999) for resident teaching Alavi-Mandell Prize (1998), Society of Nuclear Medicine Outstanding Researcher (EB-1) status (1997) Merit Scholarship for Ph.D. studies (1993) Chengazi has mentored numerous co-authors across his publications and is recognized for his contributions to nuclear medicine instrumentation and radiology education . He speaks English, Hindi, Punjabi, and Urdu, ensuring accessibility to diverse patient populations.

Zhenghong Leeمشاهده پروفایل

استاد

• Cancer Imaging
• Stem Cell Imaging
• Molecular Imaging
• +۴ مورد دیگر

Zhenghong Lee, PhD, serves as Professor in the Department of Radiology at Case Western Reserve University's School of Medicine and Associate Professor in Biomedical Engineering at the Case School of Engineering, while co-leading the Cancer Imaging Program at the Case Comprehensive Cancer Center. His expertise spans molecular imaging with specialization in PET radiotracer development, quantitative image analysis, and multimodal preclinical-to-clinical translation using micro-CT/PET/SPECT systems across diverse animal models from rodents to large mammals. Dr. Lee's educational foundation includes: Doctor of Philosophy, Case Western Reserve University (1997) Master of Science, University of Akron (1993) Bachelor of Science, Zhejiang University, China (1986) His research program integrates cancer biology with advanced imaging, focusing on mechanistic tracer uptake studies in hepatocellular carcinoma, development of dual-modality reporter systems for stem cell regeneration monitoring, and quantitative correlation of dynamic PET data with histopathology. This translational approach bridges molecular probes for lipid/amino acid metabolism with clinical oncology applications through rigorous preclinical validation. Publication analysis reveals dominant themes in liver cancer molecular imaging using radiolabeled methionine, acetate, and choline tracers, with consistent emphasis on quantitative methodology across PET, SPECT, and bioluminescence platforms. His work establishes critical links between tracer kinetics, metabolic pathways, and histological validation while pioneering stem cell tracking techniques for regenerative medicine. Professional recognition includes: Distinguished Investigator Award (2014, The Academy for Radiology and Biomedical Imaging Research) Three-time Teacher of the Year for Radiological Physics (2009, 2011, 2013, University Hospitals Cleveland) Society of Nuclear Medicine Image of the Year (2000) and SNIDD Image of the Month (1999) Dr. Lee directs a multidisciplinary imaging laboratory within the Bolwell Building, operating preclinical scanners for small/large animal studies while collaborating through the Case Comprehensive Cancer Center's imaging core. His team develops novel radiotracers and reporter gene systems to advance in vivo monitoring of tumor metabolism and stem cell therapies, maintaining active partnerships with clinical oncology and radiology departments.

• Molecular Imaging
• Nuclear Medicine
• Multimodal Imaging
• +۷ مورد دیگر

Univ.-Prof. Dr. med. Michael Andreas Schäfers is a Full Professor of Nuclear Medicine and Director of the European Institute for Molecular Imaging (EIMI) and the Department of Nuclear Medicine at the University of Münster. He holds leadership roles, including Chairman of the German Universities Nuclear Medicine National Committee and membership in multiple medical societies. His expertise spans molecular imaging, translational research, and hybrid imaging techniques. Education includes a PhD from the University of Münster (1995) and habilitation (1999). Professional milestones include research at the MRC Cyclotron Unit (London, 1994–1995) and tenure-track professorship (1999–2007). His research focuses on multimodal molecular imaging, targeted imaging probes, cardiovascular inflammation, apoptosis, and hybrid imaging technologies. Key research interests include development of radiopharmaceuticals, PET/MRI integration, and imaging of inflammatory and oncological processes. Notable contributions include studies on FAP-directed radioligand therapy, S100A8/A9 alarmins, and glutamine's role in acute kidney injury. He has authored over 300 publications and holds patents on imaging agents. Scientific awards include recognition from Focus-Ärzteliste (2022), BurdaVerlag, and the Young Investigator Award (2004). He supervises the CiM-IMPRS Graduate Programme and contributes to clinical trials in oncology and radiopharmacology. His labs at EIMI and the Translational Imaging Group advance imaging technologies and preclinical/clinical collaborations.

Donna J. Crossمشاهده پروفایل

دانشیار

• Neuroimaging
• Neurodegenerative Disorders
• Traumatic Brain Injury
• +۶ مورد دیگر

Donna J. Cross, PhD, serves as Research Associate Professor in the Department of Radiology & Imaging Sciences at the University of Utah, directing the NeuroImaging and Biotechnology Laboratory (NIBL). Her work pioneers neuroimaging applications to transform therapeutic and diagnostic approaches for neurological disorders and dementia through advanced techniques like MR-guided focused ultrasound and molecular imaging. Dr. Cross's academic foundation includes a PhD and BSE from the University of Michigan, senior fellowship training at the University of Washington, and additional studies at Michigan State University. Her educational journey established the groundwork for her innovative research in brain imaging and therapeutic development. Her research program spans neurodegenerative disorders, traumatic brain injury, and dementia, with emphasis on Alzheimer's disease mechanisms, spinal cord injury treatment via focused ultrasound, and intranasal drug delivery systems. NIBL's projects integrate molecular imaging, AI-driven analysis, and cross-species models to address critical gaps in neurological care. Recent publications demonstrate accelerating focus on AI-enhanced imaging biomarkers, avian cognition models for human brain function, and microtubule-stabilizing therapies for neurodegeneration. These works reveal growing interdisciplinary convergence between computational neuroscience, therapeutic delivery systems, and translational neurotrauma research. As 2022/2023 president of the SNMMI Brain Imaging Council and active NIH study section participant, Dr. Cross shapes national research priorities. Her laboratory receives funding from the International Atomic Energy Agency and Alzheimer's Association for multi-center dementia imaging and intranasal therapy development. NIBL operates as a multidisciplinary hub with faculty collaborators, lab technologists, and student researchers advancing seven core projects from brain mapping to traumatic injury therapeutics.

Jeffrey Yapمشاهده پروفایل

استاد پژوهشی

• Quantitative Imaging
• Cancer Therapy
• Multimodality Imaging
• +۶ مورد دیگر

Jeffrey Yap is a Research Professor in the Department of Radiology and Imaging Sciences at the University of Utah . He serves as the Director of the Center for Quantitative Cancer Imaging and Theranostics (CQCIT) , a multidisciplinary hub integrating radiopharmaceutical development, preclinical and clinical imaging, and theranostic technologies. His research focuses on quantitative multimodality imaging to evaluate novel cancer therapies in murine tumor models and clinical trials , with expertise in PET/CT, SPECT/CT, and theranostic radiopharmaceuticals . He holds a PhD in Medical Physics from the University of Chicago and a BS in Physics from the University of Dallas. Education PhD in Medical Physics, University of Chicago BS in Physics, University of Dallas Research Interests Quantitative imaging for cancer therapy evaluation Theranostics (diagnostic and therapeutic radiopharmaceuticals) 4D PET/CT in radiation treatment planning Body composition analysis in oncology Preclinical and clinical trial imaging Hypoxia and metabolic PET biomarkers Scientific Contributions Developed standardized imaging protocols for clinical trials (e.g., UPICT) Characterized autophagy resistance mechanisms in RAS-driven cancers Validated FDG-PET as a pharmacodynamic biomarker for targeted therapies Integrated body composition metrics into cancer survival analysis Laboratory & Facilities Director of CQCIT , operating two cGMP cyclotron labs North American Mediso Preclinical Imaging Center of Excellence Advanced digital PET/CT/SPECT/CT for clinical trials Image Analysis Core with Yunu software for tumor measurement

Veronika Wingstedtمشاهده پروفایل

پژوهشگر

• Nuclear Medicine
• Molecular Imaging
• Radiopharmaceutical Chemistry
• +۳ مورد دیگر

Veronika Wingstedt serves as a Researcher within the Department of Medicinal Chemistry at Uppsala University, where she contributes to the Platform for Preclinical PET-MRI. Her technical expertise focuses on engineering advanced imaging protocols for biomedical research, specifically in the development and application of multimodal imaging techniques including PET, SPECT, and CT for preclinical disease modeling and drug evaluation. Her core research spans Nuclear Medicine , Molecular Imaging , and Radiopharmaceutical Chemistry , with specialized contributions in radiotracer synthesis (particularly C-11 and Ga-68 compounds), bone regeneration imaging, cancer theranostics, and endocrine disorder diagnostics. She integrates radiochemistry with molecular biology to develop imaging probes for bone morphogenetic protein tracking, insulinoma detection, and HER2-targeted prostate cancer therapy, emphasizing translational applications from preclinical validation to clinical feasibility studies. Analysis of her publication timeline (2012-2018) reveals consistent innovation in multimodal imaging probe development, with increasing focus on theranostic applications. Her work demonstrates methodological rigor in dosimetry calculations, radiolabeling optimization, and validation of imaging protocols across diverse disease models. Key thematic threads include the engineering of tri-modal visualization systems, precision targeting of molecular pathways in cancer, and quantitative assessment of physiological processes like cerebral blood flow during surgical interventions. No scientific awards, fellowships, or medals are documented in the provided materials. The available information does not specify graduate student advising relationships or external grant funding, though her extensive collaborative publication record indicates active participation in multidisciplinary research teams. As a core technical contributor to Uppsala University's Platform for Preclinical PET-MRI, Wingstedt supports biomedical research through state-of-the-art imaging infrastructure. This platform enables high-resolution quantitative studies across oncology, endocrinology, and bone disease research, with her engineering expertise directly enhancing capabilities in radiotracer development, multimodal imaging protocol design, and preclinical model validation.

• Bone Scintigraphy
• Prostate Cancer
• Bone Metastasis
• +۵ مورد دیگر

Henrik Christian Bertelsen serves as Chief Physician (Cheflæge) at Aalborg University Hospital within The Faculty of Medicine's Department of Nuclear Medicine. His clinical and research career spans over 15 years with consistent scholarly output from 2007 through 2022. His institutional affiliation connects clinical practice with academic research in nuclear medicine diagnostics. Dr. Bertelsen's research interests center on advanced diagnostic imaging applications, particularly focusing on Bone Scintigraphy, Prostate Cancer imaging, Bone Metastasis detection, and Single Photon Emission Computed Tomography-Computed Tomography techniques. His work emphasizes prospective clinical studies to validate diagnostic approaches across multiple medical specialties including orthopedics, oncology, and endocrinology. Analysis of his publication record reveals a strong focus on translating nuclear medicine techniques into clinical practice, with particular emphasis on improving diagnostic accuracy for complex conditions including prosthetic joint infections, prostate cancer progression, and parathyroid disorders. His research demonstrates consistent collaboration with multidisciplinary teams across medical specialties. Dr. Bertelsen has participated in significant research activities including conference presentations at EANM kongres 2011 and DRS og DSKFNM årsmøde in 2014, along with delivering lectures on hybrid molecular imaging techniques. His scholarly contributions include serving on the hospital physician council (Overlægerådets bestyrelse) from 2006-2007 and participating in educational courses for training responsible senior physicians. His research has been cited extensively across various platforms, with notable mentions in policy documents, news outlets, and patent references, demonstrating real-world impact of his work in nuclear medicine diagnostics.

Christina Baunمشاهده پروفایل

پژوهشگر

• Nuclear Medicine
• Molecular Imaging
• Breast Cancer
• +۱۲ مورد دیگر

Christina Baun is a researcher affiliated with the Department of Clinical Research at the University of Southern Denmark (Syddansk Universitet), with visiting researcher status at Karolinska Institutet (KI) and Odense University Hospital (OUH). Her work is centered on molecular imaging and nuclear medicine, particularly in the context of cancer theranostics. She is actively involved in preclinical and clinical research on breast cancer, focusing on the gastrin-releasing peptide receptor (GRPR) as a target for imaging and therapy. Research Interests: Her research spans translational and clinical molecular imaging , with a focus on PET, SPECT, and CT technologies. She investigates theranostic applications in breast cancer, especially estrogen receptor-positive subtypes, and explores person-centered care in diagnostic nuclear medicine. Her work integrates radiopharmaceutical development, preclinical evaluation, and clinical implementation. Recent Research Trends: Analysis of her recent publications reveals a strong emphasis on GRPR-targeted radioligands like RM26, the use of isotopes such as 55 Co and 177 Lu, and the expansion of theranostic strategies in oncology. She also contributes to public science communication and education, particularly in radiography and bioimaging. Mallinkrodt European Technologist Award 2015 EANM Technologist Poster Prize 2009 Teaching and Supervision: Christina has taught in interdisciplinary settings, including the Cross Institutional Bioimaging course and Evidence-Based Radiography . While no formal advisees are listed, her educational activities suggest active mentorship. She has not received mention of external grants, but her involvement in projects like GATEBA and LUTEBA indicates research funding support. Collaborative Networks: She collaborates extensively with researchers across Denmark and internationally, particularly in nuclear medicine and oncology. Her work is embedded in a strong institutional network involving SDU, OUH, and KI, and she participates in national science outreach initiatives.

Len Luytمشاهده پروفایل

استاد

• Organic Chemistry
• Medicinal Chemistry
• Radiopharmaceutical Chemistry
• +۵ مورد دیگر

Professor Len Luyt serves as a faculty member in the Department of Chemistry at Western University, with cross-appointments in Oncology and Medical Imaging. His research laboratory is located at the London Regional Cancer Program (LRCP) within the Cancer Research Laboratories. Dr. Luyt leads an active research group focused on developing novel chemical entities for cancer imaging and therapy. Dr. Luyt received his B.Sc.(Eng.) from Queen's University, followed by a Ph.D. in Chemistry from The University of Western Ontario under the mentorship of Prof. Duncan Hunter. He completed his postdoctoral fellowship with Prof. John Katzenellenbogen at the University of Illinois, Urbana-Champaign. Prior to joining Western University in 2005, he worked as a Senior Medicinal Chemist at Bayer-Schering. His research program focuses on three primary areas: developing imaging agents targeting the ghrelin receptor (GHSR), exploring metal-organic compounds as scaffolds for biologically relevant chemical space, and creating peptide drugs that interfere with RHAMM:Hyaluronan interactions. His work bridges synthetic organic chemistry with molecular imaging and cancer therapeutics, specifically targeting peptide receptors on cancer tumor cells through radiolabeled compounds. The group develops compounds that can be used for positron emission tomography (PET) imaging and potential cancer treatments. An analysis of Dr. Luyt's recent publications reveals a strong focus on molecular imaging agents, particularly for cancer diagnostics. His work spans multiple imaging modalities including PET, fluorescence, and SPECT imaging. A significant portion of his research targets the ghrelin receptor in prostate cancer, while other work explores novel chemical methodologies for radiolabeling peptides and developing metal-organic complexes for imaging applications. His research demonstrates a consistent trajectory from basic chemical synthesis through to applied preclinical studies. Innovator of the Year, Vanguard Awards (WorlDiscoveries) Early Researcher Award Dr. Luyt actively mentors graduate students and postdoctoral fellows in his research laboratory. His group consists of multiple graduate students working on various aspects of cancer imaging agent development, including peptide synthesis, radiolabeling techniques, and biological evaluation. The research requires interdisciplinary collaboration with cancer biologists, imaging scientists, and clinicians to take projects from basic chemistry through to animal model studies. His laboratory at the London Regional Cancer Program provides students with training in synthetic organic chemistry, solid-phase organic chemistry, peptide/peptidomimetic design, bioconjugation, and radiolabeling techniques. The Luyt Laboratory operates within the London Regional Cancer Program's Cancer Research Laboratories, providing state-of-the-art facilities for synthetic chemistry and radiopharmaceutical development. The research group collaborates extensively with other scientists at Western University and the Lawson Health Research Institute, creating a multidisciplinary environment focused on translating chemical discoveries into potential clinical applications for cancer imaging and therapy.

Geoff Currieمشاهده پروفایل

استاد

• Nuclear Medicine
• Molecular Imaging
• Artificial Intelligence in Medical Imaging
• +۶ مورد دیگر

Professor Geoff Currie is a distinguished academic and researcher in Nuclear Medicine at Charles Sturt University's School of Dentistry and Medical Sciences, with an adjunct professorship in Radiology at Baylor College of Medicine in Houston, Texas. With over two decades of experience in academia, clinical practice, and research, Professor Currie has established himself as a global leader in medical radiation sciences and artificial intelligence applications in nuclear medicine. Professor Currie's educational background includes: BPharm (Bachelors Degree in Pharmacy) MMedRadSc(NucMed) (Masters in Medical Radiation Science - Nuclear Medicine) MAppMngt(Hlth) (Masters in Applied Management - Health) MBA (Masters in Business Administration) PhD (Doctor of Philosophy) Professor Currie's research spans multiple domains within medical radiation sciences, with particular emphasis on nuclear medicine, molecular imaging, artificial intelligence applications, and theranostics. His work bridges clinical practice with technological innovation, especially in the integration of AI and machine learning into nuclear medicine workflows. His research has significant implications for cancer diagnostics, cardiovascular imaging, and personalized medicine approaches, with recent focus on prostate cancer detection, theranostic applications, and addressing biases in AI-generated medical imagery. Professor Currie has received numerous accolades including the Member of the Order of Australia (AM) in 2020 for services to nuclear medicine, "Outstanding Educator" by SNMMI-TS in 2020, Editor's Choice Award for Best Educators Paper in 2023, and Fellow of the SNMMI-TS (USA) in 2023. Member of the Order of Australia (AM), 2020 Outstanding Educator Award, SNMMI-TS, 2020 Editor's Choice Award for Best Educators Paper, 2023 Fellow of the SNMMI-TS (USA), 2023 Australian Government Microcredentials in Higher Education Pilot grant, 2023 Commonwealth supported places under Nuclear-Powered Submarines Student Pathways program, 2024 As a dedicated educator and research supervisor, Professor Currie has mentored numerous doctoral, masters, and honours students. He has secured over $6.7 million in research funding and has been instrumental in developing innovative educational programs including professional portfolios for undergraduate students, internationalization programs in New Zealand, London and the USA, and pioneering evaluations of mobile learning technologies. He currently leads initiatives related to the AUKUS nuclear submarine project workforce development, creating microcredential pathways and new courses in nuclear science and safety. Professor Currie co-founded RAINS (Radiology Artificial Intelligence Network Society) and serves as International Consulting Editor for the Journal of Nuclear Medicine Technology (JNMT). He is also a member of the ANSTO Health Advisory board. His current research highlights include the NOBLE (Nobody Left Behind) international trial investigating prostate cancer detection using [99mTc]Tc-HYNIC-iPSMA SPECT imaging across 10 countries, where Charles Sturt University partners with TeleMed Health Services for the Australian arm.

Mona Elisabeth Rootwelt-Revheimمشاهده پروفایل

استاد

• Nuclear Medicine
• PET Imaging
• Molecular Imaging
• +۵ مورد دیگر

Mona Elisabeth Rootwelt-Revheim serves as Professor II at The Intervention Centre, Faculty of Medicine, University of Oslo. Her work bridges clinical medicine with advanced imaging technologies, focusing on innovative applications of nuclear medicine techniques across multiple medical specialties. Her research spans diverse areas including neuroimaging, oncology imaging, cardiovascular applications, and psychiatric disorders. Dr. Rootwelt-Revheim has made significant contributions to understanding PET imaging applications in conditions ranging from Alzheimer's disease and Parkinson's to cancer diagnostics and treatment monitoring. Her work particularly emphasizes the clinical translation of molecular imaging techniques to improve patient diagnosis and management. Analysis of her recent publications reveals a strong focus on advancing PET imaging methodologies across neurological disorders, cancer therapeutics, and inflammatory conditions. Her research demonstrates how molecular imaging can provide critical insights into disease mechanisms while offering practical clinical applications for diagnosis and treatment monitoring. Dr. Rootwelt-Revheim maintains active collaborations with leading researchers in nuclear medicine globally, particularly with Poul Flemming Høilund-Carlsen, Abass Alavi, and Thomas J. Werner. Her work at The Intervention Centre positions her at the forefront of developing and applying novel imaging techniques to address complex clinical challenges.

Nancy Carrascoمشاهده پروفایل

استاد

• Sodium/Iodide Symporter (NIS) research
• Thyroid Hormone Biosynthesis
• Cancer Treatment Applications
• +۳ مورد دیگر

Nancy Carrasco, M.D., is a Professor and Chair of the Department of Molecular Physiology and Biophysics at Vanderbilt University School of Medicine. She holds the Joe C. Davis Chair in Biomedical Science. Her research focuses on the sodium/iodide symporter (NIS), its structural and functional properties, and its role in thyroid hormone biosynthesis, cancer treatment, and metabolic health. Her work integrates molecular biology, genetics, and translational medicine to address endocrine disorders and oncological challenges. Key areas of investigation include NIS-mediated iodide transport mechanisms, the impact of environmental pollutants like perchlorate on thyroid function, and the development of NIS-based therapies for cancer and metabolic diseases. Carrasco’s studies also explore the physiological adaptations of the thyroid under nutritional stress and the role of metabolic pathways in obesity-related conditions. Her research has advanced understanding of NIS mutations causing congenital iodide transport defects and pioneered the use of NIS as a therapeutic target in breast cancer and thyroid disorders. Collaborative projects include gene therapy approaches using AAV9 vectors and imaging techniques like SPECT/CT for NIS expression quantification. Notable contributions include identifying NIS’s role in regulating cancer cell invasiveness, elucidating structural insights into NIS transport cycles via cryo-EM and computational modeling, and discovering metabolic adaptations in hypothyroid mice. Her work bridges basic science and clinical application, aiming to improve diagnostic and therapeutic strategies for endocrine and oncological diseases.

• Medical Protein Technology
• Cancer Therapy
• Drug Delivery Systems
• +۳ مورد دیگر

Torbjörn Gräslund is a Professor of Medical Protein Technology at KTH Royal Institute of Technology . His work focuses on designing protein-based molecules for medical applications, particularly in cancer therapy and diagnosis. His research group develops drug conjugates targeting HER2 and EpCAM receptors, with an emphasis on minimizing healthy tissue impact while maximizing tumor efficacy. Key research areas include the development of targeted toxins, pretargeting strategies for cytotoxic drug delivery, and optimizing radiolabeling techniques for PET and SPECT imaging. He explores molecular design principles to enhance drug conjugate half-life and tumor uptake through albumin-binding domains (ABD) and protein fusion technologies. His articles highlight advancements in HER2/HER3-targeted therapies, albumin-binding domain applications, and novel imaging probes for oncological diagnostics. Collaborations involve interdisciplinary projects combining protein engineering with preclinical testing in mice models. Notable research contributions include the evaluation of Affibody molecules as therapeutic and diagnostic agents, and the use of designed proteins like DARPins for EpCAM imaging in pancreatic and prostate cancers. No scientific awards or grants are explicitly mentioned in the provided texts, though his extensive publication record indicates impactful work.